our today made since disease major NDA in Society all meeting for initiatives and include Program XXXX the you including awareness half today. of American Approval weeks us upcoming last of conference I'm activities the that update campaign prelaunch of the TRCXXX, and pleased significant Jackie, ago. thank the quarterly our for Accelerated successful of joining start at you, second the and call, submission Thank Nephrology under on progress XXXX, X to our you We've
you launch related serum the thereby, engaged bicarb and TRCXXX we're the CKD. dosed treat to acidosis. of effectively acid the with TRCXXX. orally patients once-daily levels by TRCXXX in to landscape slow hydrochloric awareness in and potentially tract metabolic XXXX, for our and shown of additional campaign analyses and for works the As is of trials the a know, disease and progression clinical our metabolic acidosis half polymer from have in removing NDA now and planned many of health non-absorbed GI of With non-branded increase safely number been including payer economics submission designed activities, both, second to binding
which key elements educational review campaign, The acidosis awareness now this Let Neph+. new our the strongly me initial of video elements app as our a positive the the as metabolic mobile of link received reception discussing at well between called progression CKD and included disease meeting. ASN campaign
Wesson Bushinsky, and nine and is also video link our awareness new as acidosis minute of clear in progression awareness disease purview metabolicacidosisinsight.com. Tangri disease the the three This Dr. metabolic now CKD. the video nephrologists, and features of provides Our available prominent company website, between
Google end-stage from serum attendees. recommendations a the levels key uses and a individual designed day introduction. the were of Neph+ the progression meeting CKD meeting, patient's embracing Neph+ extensive to By CKD. equations Tricida contributor of were completing the app To and over app the the specifically patients patient's renal new innovative asking our establish be or XXXX It final cost this advance change features education the There the can also patient very with the disease. mobile eight Play. metabolic this among a optimize and to summary to The to can for KDIGO tool, the variable app five guideline to acidosis. progression effect failure booth Store of as kidney equations commonly risk to app popularity quantifying providers pleased nephrology continue continued eGFR education awareness, We ESRD. update potential of healthcare maintain we're mobile of days first quantify other new and savings to for the to to just downloaded important nephrology significant the within further ASN were it. a variables, of bicarb such the second of Our among in community app nephrologists care about help quantify Apple age of in app new stages the and connection The contains enthusiastically downloads coming broader risk Neph+ of prelaunch the as with the a how treatment nephrologists. pharmacoeconomic to a App an plans, used commercial for We'll
additional are in from of reimbursement our first this We the work iteration to the and half plan XXXX. third and of pricing wrapping get input engagement payer
our Of course, TRCXXX. predicated of activities prelaunch upon all approval are the
in XX-month of year. stability trial year, which the next half So key submission that the in XXXX; availability the first NDA achieve to to with our now or of I'd concurrent of remain of of second our is on in our the of half XXXX enable to safety middle of with milestones TRCA-XXX ongoing track planned of which both our half NDA, of towards submission. like VALOR-CKD activities second and our registration turn include trial for the We submission, will are three on associated the which track the our NDA the near-completion data enrollment completion extension completion
CKD metabolic is primary moment known of in to TRCXXX evaluate a treated trial, let delaying VALOR-CKD The is also TRCA-XXX. in progression the safety the event review patients is to and of first trial Now patients TRCXXX in step with the time a It renal of intended design endpoint versus me for which with back placebo. as pre-dialysis the to efficacy acidosis.
We placebo, progression event XXXX. to that study TRCXXX a is VALOR-CKD half complete a GFR order XX% years defined estimate renal to a the taking as or death. disease, to a reduction XX% it anticipate either of this randomize four reading greater rate with and in event equal that post-marketing to that show or that taking remember is in out estimated will with data will Please we renal take approximately in the TRCXXX. approximately approximately is X,XXX renal trial. trial, to need renal For reduction ESRD, or with We end-stage XX% to purposes subjects half
reminder, our successful Approval U.S. As assuming of Program, the half an approval TRCXXX a Accelerated and of initial XXXX. we second launch target for
on and York investigator patients. investigators months coming end clinical This Several screening the now the includes recruitment meeting and sites week enrolling meeting milestone in of last the the various Eastern screening first for our trial. in countries, European City of health in just Central investigators. completed and authority New obtaining initiating at in VALOR-CKD an Rome September and study approvals patients. focus Our We are committee sites and is ethics hosted
the enrollment now to and initiate first in time the year. majority given We Phase end achievable XXXX, the enrollment number patients the site to up that the are a expect third XXX at in the XXXX. targets sites enrolled in and VALOR-CKD end of between So We meaningful the pre-identified expected frame, sites match be to quarter we patients. the means trial patient trial our most these global in on that quarters beginning anticipate in plan of the conducted we of to will The scale trial be enrollment second XX of we of per our VALOR-CKD the of trial potential recruitment as pace before countries. have III and which of a believe, is
is It now TRCXXX. a of of first ongoing that to in a we as This the for conduct with completion the our long-term FDA XXXX. half Turning to trial blinded on track study TRCA-XXX safety-extension is agreed trial.
of in NDA. We will results submit the study this the
the measurements we measures endpoints would patient-reported also on disease data, of are these for results survey, our substantiate CKD measured potential test. post-hoc for a repeated we and further I'll In on new physical physical in objectively treatment the the the not chair endpoint, repeated and These the is minute, NDA required life submission, stand NDA the of duration based required benefits on a positive that evaluate presented of data double-blind III of the but Late-Breaking kidney new And function the analysis results, secondary the in submission, the metabolic effect quality blood clinical and bicarbonate will try as we KDQOL KDQOL function believe, were see patients at study interest describe the the addition with safety of in III we to met or two of functioning, of to the data acidosis. trial field trials With in TRCXXX which to study, Phase III Phase and hopeful, Phase placebo-controlled our our the nephrology clinical plan a from Clinical results are test endpoint community for chemical indications entity ASN the Trial one endpoint we statistical of The endpoint. poster will refined positive the in in analysis stand well as constituted respect survey nephrology this meeting. the session year. great and completed the this were that this have strong also by benefit physical chair extension few
primary month with you statistical survey. the know, study feel the the exploratory along met this TRCXXX based how and for and that with KDQOL secondary patients function, the As of report physical at on prespecified function significance, high patient evaluated the endpoints endpoint
The was using with we two test. repeated time placebo, patients statistical missed Patients five of stand improved the time for repetitions. a weeks measured XX significance a the treated in sit-to-stand physical groups. comparing complete versus although measure to second corresponding function just exploratory TRCXXX chair It endpoint objective
the to analysis compared a a significant data, group. which group method conducted now on actual be statistical highly not of normal more statistically recently to distribution. in TRCXXX rank-based treated difference we a were However, the appropriate we results placebo analysis based post-hoc the in resulted believe of that rank-based favor This patient in these
again As normal the we have now distribution. the the in a event the fit once from data TRCA-XXXE such, results in not do trial method patient the included that statistical
a well-recognized that announced when of excited we I'm Further medical have the very TRCA-XXX Additionally, this prestigious will journal. date. publication the details study for be by publication news results been know to accepted from report the
make continue So to great summarize, TRCXXX progress patients. to bringing to towards we
are value payer first-in-class progression. for with slow potentially conducting potential patients On the disease related CKD kidney to we front, our the to acidosis needs additional and metabolic for treatment pre-commercial analyses proposition and
with the first We plan in app. are mobile and disease underway complete half of Our efforts the year. introduction of to next Neph+ study metabolicacidosisinsight.com website awareness our TRCA-XXXE
by complete I'll plan trial, of to we which next soon be year, complete to Our With year. half VALOR-CKD as that, stability for the second enrollment turn the scheduled studies nearly mid-next NDA and is as are call or to planned over Jeff. the submit complete the we in
